This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Chongqing Fagen Biomedical Inc.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations of Honghong Liu in Biomedical Science
Introduction
Honghong Liu is a prominent inventor based in Chongqing, China. He has made significant contributions to the field of biomedical science, particularly in the development of novel therapeutic proteins. His work focuses on addressing critical health issues such as obesity and diabetes.
Latest Patents
Honghong Liu holds a patent for a fusion protein of human fibroblast growth factor-21 and exendin-4. This innovative fusion protein comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. The medicament composition that includes this fusion protein can be utilized for treating or preventing obesity, diabetes, hyperglycemia, and hyperlipidemia, among other conditions. He has 1 patent to his name.
Career Highlights
Liu is associated with Chongqing Fagen Biomedical Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on public health.
Collaborations
Some of his notable coworkers include Kai Fan and Zhiquan Zhao, who contribute to the innovative environment at Chongqing Fagen Biomedical Inc.
Conclusion
Honghong Liu's contributions to biomedical science through his innovative patent highlight the importance of research in developing effective treatments for prevalent health issues. His work exemplifies the potential of scientific innovation to improve health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile